معرفی
Dominik Wenisch is an active researcher at the University of Vienna's Faculty of Chemistry, Institute of Inorganic Chemistry. Holding BSc and MSc credentials, he contributes significantly to medicinal inorganic chemistry research with focus on anticancer compounds.
His research spans multiple areas in drug development, particularly exploring ruthenium-based complexes and metal chelators for cancer treatment. Key interests include reactive oxygen species modulation, naphthoquinone stability, lipophilicity effects, and density functional theory applications in drug design. His work directly contributes to Sustainable Development Goals related to good health and well-being.
Recent publications demonstrate strong focus on metal-based anticancer agents, with several 2024 papers examining iron chelators, flavan-benzofurans, and gold-templated targeting of cancer cell enzymes. His research shows consistent output with 14 publications between 2020-2024 and upcoming presentations scheduled for 2025.
- Ruthenium Chemistry (primary focus)
- Reactive Oxygen Species modulation
- Anticancer drug mechanisms
- Organometallic complex development
- Natural product pharmacology
As part of the research team led by established investigators including Michael Jakupec and Bernhard Keppler, Wenisch contributes to multiple collaborative projects investigating novel therapeutic approaches for cancer treatment through metal-based compounds and natural product derivatives.